Furthermore, the elevation of CX3CL1 exclusively in the AD population supports its utility as an independent staging biomarker, which means that by rapid testing of CX3CL1 protein levels may enable earlier patient stratification. The gene discussed is CX3CL1; the disease is Alzheimer disease.